Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult male patients with Tourette Syndrome (TS)

Next Previous
X
Search
Trial Profile

An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult male patients with Tourette Syndrome (TS)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemlapodect (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Acronyms Allevia; NOE-TTS-211
  • Sponsors Noema Pharma

    • Most Recent Events

    • 24 Apr 2024 This trial has been completed in Germany (Global end date: 3 Apr 2024).
    • 21 Jun 2023 According to a Noema Pharma media release, company has completed this trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort.
    • 05 Jan 2023 According to a Noema Pharma media release, trial has been completed in adult patients with Tourette Syndrome.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top